Key Highlights
- Abcuro raises $200M in Series C funding led by New Enterprise Associates (NEA) with participation from Foresite Capital and existing investors.
- Funding supports Phase 2/3 MUSCLE trial for ulviprubart (ABC008) in inclusion body myositis (IBM).
- Ulviprubart is a first-in-class monoclonal antibody targeting KLRG1 to selectively deplete cytotoxic T cells.
- Initial data expected in H1 2026, with a potential Biologics License Application (BLA) filing upon positive results.
- Funds will also support manufacturing expansion and pre-commercial activities.
Source: Business Wire
Notable Quotes
- “Continued support from all of our investors in this latest financing round validates our vision for the potential that ulviprubart may have as a novel treatment for progressive and devastating diseases mediated by highly cytotoxic T cells, including Inclusion Body Myositis.” — Alex Martin, Chief Executive Officer at Abcuro
- “Abcuro represents an exciting opportunity with its lead candidate, ulviprubart, a potential first-in-class therapy that could make a big impact to the treatment paradigm of IBM, an indication with a significant unmet clinical need.” — Michele Park, PhD, Partner at NEA
Why This Matters
Inclusion body myositis (IBM) is a debilitating autoimmune disease with no disease-modifying treatments currently available. With the FDA and EMA granting orphan drug designation to ulviprubart, Abcuro’s funding milestone marks a major step forward in developing a potential first-in-class therapy for IBM patients. This investment not only accelerates clinical trials but also positions Abcuro for future commercialization, addressing a significant unmet medical need in neuromuscular diseases.
